Product Code: GVR-4-68039-297-3
Healthcare Analytical Testing Services Market Growth & Trends:
The global healthcare analytical testing services market size is expected to reach USD 25.1 billion by 2030, registering a CAGR of 8.3% over the forecast period, according to a new report by Grand View Research, Inc. The increasing outsourcing of healthcare analytical testing services, growing demand for biosimilars, and rising number of clinical trials are some of the key factors that are driving the industry's growth. In addition, the COVID-19 pandemic contributed to the growth of the industry. Biosimilars are medications that have received FDA approval and share many biologic medicines' approved features. When compared to biologics, they are a more affordable and effective treatment alternative, and it is projected that this will significantly increase demand in the coming years.
Analytical testing is highlighted as a crucial step in the development of biosimilars in a Sandoz International GmbH article, which increases demand for such services. The global COVID-19 pandemic is expected to offer high growth opportunities to the providers of such services. As pharmaceutical companies across the world have started clinical trials for the development of vaccines therapeutics, and medications for the treatment of COVID-19, the demand for analytical testing has increased. Also, to combat the coronavirus, the growing need to meet the global requirements of medical devices and pharmaceutical products, which must undergo rigorous testing before being distributed to customers, has boosted the production in the industry. This, in turn, is expected to augment the demand for such services.
Healthcare Analytical Testing Services Market Report Highlights:
- The medical device and pharmaceutical market has strict regulations so they are adopting analytical testing services that are driving the market growth
- The Pharmaceutical Analytical Testing Services market held the largest market share of 58.5% in 2021
- North America dominated the global market with the largest revenue share of 53.7% in 2021 owing to the presence of the largest clinical trials market in the U.S.
- The Asia Pacific region is anticipated to grow at the fastest CAGR of 9.5% during the forecast period
- This growth can be credited to the development and expansion of new facilities in different countries present in this region
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Region scope
- 1.1.3. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1: Understanding the market dynamics
- 1.9.2. Objective 2: Understanding the market estimates and forecasts
- 1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
- 1.9.4. Objective 4: Understanding the key service and type scopes to conclude on the market size.
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Healthcare Analytical Testing Services Market Variables, Trends & Scope
- 3.1. Penetration & Growth Prospect Mapping
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.2.3. Industry challenges
- 3.3. Healthcare Analytical Testing Services Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Major Deals & Strategic Alliances Analysis
- 3.3.4. COVID- Impact Analysis
Chapter 4. Healthcare Analytical Testing Services Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Healthcare Analytical Testing Services Market Share, 2021 & 2030
- 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.3.1. Medical Device Analytical Testing Services
- 4.3.1.1. Extractable & Leachable
- 4.3.1.2. Material Characterization
- 4.3.1.3. Physical Testing
- 4.3.1.4. Bioburden Testing
- 4.3.1.5. Sterility Testing
- 4.3.1.6. Other Tests
- 4.3.2. Pharmaceutical Analytical Testing Services
- 4.3.2.1. Bioanalytical Testing
- 4.3.2.2. Method Development & Validation
- 4.3.2.3. Stability Testing
- 4.3.2.4. Other Testing Services
Chapter 5. Healthcare Analytical Testing Services Market: Regional Estimates & Trend Analysis
- 5.1. Regional Market Dashboard
- 5.2. Regional Market Share Analysis, 2021 & 2030
- 5.3. North America
- 5.3.1. Market estimates and forecast by country, 2018 - 2030 (USD Million)
- 5.3.2. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.3.3. U.S.
- 5.3.3.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.3.4. Canada
- 5.3.4.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.4. Europe
- 5.4.1. Market estimates and forecast by country, 2018 - 2030 (USD Million)
- 5.4.2. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.4.3. U.K.
- 5.4.3.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.4.4. Germany
- 5.4.4.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.4.5. France
- 5.4.5.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.4.6. Italy
- 5.4.6.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.4.7. Spain
- 5.4.7.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.5. Asia Pacific
- 5.5.1. Market estimates and forecast by country, 2018 - 2030 (USD Million)
- 5.5.2. India
- 5.5.2.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.5.3. Japan
- 5.5.3.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.5.4. China
- 5.5.4.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.5.5. Australia
- 5.5.5.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.5.6. South Korea
- 5.5.6.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.6. Latin America
- 5.6.1. Market estimates and forecast by country, 2018 - 2030 (USD Million)
- 5.6.2. Brazil
- 5.6.2.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.6.3. Mexico
- 5.6.3.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.6.4. Argentina
- 5.6.4.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.6.5. Colombia
- 5.6.5.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.6.6. Chile
- 5.6.6.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.7. MEA
- 5.7.1. Market estimates and forecast by country, 2018 - 2030 (USD Million)
- 5.7.2. South Africa
- 5.7.2.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.7.3. Saudi Arabia
- 5.7.3.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
- 5.7.4. UAE
- 5.7.4.1. Market estimates and forecast by type, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis, By Key Market Participants
- 6.1.1. Pharmaceutical Product Development
- 6.1.1.1. Company overview
- 6.1.1.2. Financial performance
- 6.1.1.3. Product benchmarking
- 6.1.1.4. Strategic initiatives
- 6.1.2. ICON plc
- 6.1.2.1. Company overview
- 6.1.2.2. Financial performance
- 6.1.2.3. Product benchmarking
- 6.1.2.4. Strategic initiatives
- 6.1.3. LabCorp
- 6.1.3.1. Company overview
- 6.1.3.2. Financial performance
- 6.1.3.3. Product benchmarking
- 6.1.3.4. Strategic initiatives
- 6.1.4. Charles River Laboratories International Inc.
- 6.1.4.1. Company overview
- 6.1.4.2. Financial performance
- 6.1.4.3. Product benchmarking
- 6.1.4.4. Strategic initiatives
- 6.1.5. Syneos Health
- 6.1.5.1. Company overview
- 6.1.5.2. Financial performance
- 6.1.5.3. Product benchmarking
- 6.1.5.4. Strategic initiatives
- 6.1.6. SGS SA
- 6.1.6.1. Company overview
- 6.1.6.2. Financial performance
- 6.1.6.3. Product benchmarking
- 6.1.6.4. Strategic initiatives
- 6.1.7. Toxikon, Inc.
- 6.1.7.1. Company overview
- 6.1.7.2. Financial performance
- 6.1.7.3. Product benchmarking
- 6.1.7.4. Strategic initiatives
- 6.1.8. Intertek Group
- 6.1.8.1. Company overview
- 6.1.8.2. Financial performance
- 6.1.8.3. Product benchmarking
- 6.1.8.4. Strategic initiatives
- 6.1.9. Pace Analytical Services, LLC
- 6.1.9.1. Company overview
- 6.1.9.2. Financial performance
- 6.1.9.3. Product benchmarking
- 6.1.9.4. Strategic initiatives
- 6.1.10. Eurofins Scientific
- 6.1.10.1. Company overview
- 6.1.10.2. Financial performance
- 6.1.10.3. Product benchmarking